Urticaria Market Report 2026

The urticaria market size has grown rapidly in recent years. It will grow from $4.76 billion in 2025 to $5.61 billion in 2026 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to increasing prevalence of allergic skin conditions, wider use of antihistamines, expansion of dermatology treatment services, rising awareness of chronic urticaria, availability of prescription therapies.

The urticaria market size is expected to see rapid growth in the next few years. It will grow to $10.71 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing adoption of biologic treatments, rising demand for long-acting therapies, growing focus on immune-modulating drugs, expansion of specialty dermatology clinics, increasing investment in allergy and immunology research. Major trends in the forecast period include increasing development of biologic and monoclonal antibody therapies, growing use of personalized treatment approaches, rising focus on chronic urticaria management, expansion of advanced antihistamine formulations, enhanced emphasis on long-term disease control.

The growing awareness and treatment of skin diseases are expected to drive the expansion of the urticaria market in the coming years. Rising pollution contributes to an increase in skin allergies and conditions, which in turn fuels the demand for awareness initiatives and advanced treatment options. Urticaria plays a role in promoting skin disease awareness and treatment by highlighting immune system responses, supporting research, improving diagnostics, and advancing targeted therapies. For example, in February 2024, The Skin Cancer Foundation, a US-based nonprofit, reported that 1 in 5 Americans develop skin cancer by age 70, with over two deaths occurring every hour in the U.S. This underscores the critical need for preventive measures, as experiencing five or more sunburns doubles the risk of melanoma. Therefore, the rise in skin disease awareness and treatment is driving the growth of the urticaria market.

Key companies in the urticaria market are prioritizing the development of innovative solutions, such as mast cell inhibitor antibodies, to create advanced therapeutic options for managing chronic spontaneous urticaria by targeting mast cell activation. A mast cell inhibitor antibody is a monoclonal antibody that blocks mast cell activation or degranulation by inhibiting specific receptors or signaling pathways, thereby reducing allergic reactions, inflammation, and other mast cell-mediated disorders. For instance, in May 2024, Allakos Inc., a US-based biotechnology company, announced the start of a Phase 1 clinical trial for AK006, designed to treat chronic spontaneous urticaria (CSU). This therapy targets both IgE-dependent and IgE-independent mast cell activation pathways, offering potential benefits for patients who do not respond to antihistamines or previous biologic treatments. By selectively inhibiting mast cell activity through the Siglec-6 receptor, AK006 aims to provide a more comprehensive and long-lasting approach to CSU management, representing a major advancement in urticaria treatment and immunotherapy research.

In April 2024, Incyte Corporation, a US-based biopharmaceutical company, acquired Escient Pharmaceuticals for $750 million. This acquisition is intended to strengthen Incyte Corporation’s portfolio in inflammation and autoimmunity (IAI) by advancing first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) and Mas-related G protein-coupled receptor X4 (MRGPRX4) antagonists, which may improve treatments for chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), atopic dermatitis (AD), cholestatic pruritus, and other inflammatory conditions. Escient Pharmaceuticals is a US-based clinical-stage biotechnology company focused on developing small-molecule therapies for chronic urticaria and severe pruritus.

Major companies operating in the urticaria market are Sanofi S.A., Novartis AG, GlaxoSmithKline PLC, Roche Holding AG, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Incyte Corporation, Kyowa Kirin Co. Ltd, Argenx SE, Allakos Inc, AstraZeneca plc, Kiniksa Pharmaceuticals Ltd, United BioPharma Inc, Celldex Therapeutics Inc, Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co Ltd, Evommune Inc, Rapt Therapeutics Inc, Enanta Pharmaceuticals Inc, UCB Pharma.

North America was the largest region in the urticaria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urticaria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the urticaria market by increasing costs of imported pharmaceutical ingredients, biologic drugs, specialty chemicals, and manufacturing equipment used in dermatology treatments. Pharmaceutical manufacturers and healthcare providers in North America and Europe are most affected due to reliance on imported active ingredients, while Asia-Pacific faces cost pressures in drug production and exports. These tariffs are raising treatment costs and influencing pricing strategies. However, they are also encouraging domestic drug manufacturing, regional sourcing of ingredients, and development of affordable therapeutic alternatives.

The urticaria market research report is one of a series of new reports that provides urticaria market statistics, including urticaria industry global market size, regional shares, competitors with a urticaria market share, detailed urticaria market segments, market trends and opportunities, and any further data you may need to thrive in the urticaria industry. This urticaria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urticaria, also known as hives, is a skin disorder marked by red, itchy, and raised welts. It arises from allergic reactions, stress, or unknown factors, which trigger histamine release. The condition can be acute (lasting less than six weeks) or chronic (lasting longer than six weeks). Treatment options include antihistamines, avoidance of triggers, and in severe cases, corticosteroids or immunotherapy.

The primary forms of urticaria are acute urticaria and chronic urticaria. Acute urticaria is a sudden-onset skin condition that lasts less than six weeks, featuring red, itchy, and swollen welts, often caused by allergic reactions, infections, medications, insect stings, or food allergens. Treatments include drug classes such as antihistamines, anti-inflammatory medications, antidepressants, monoclonal antibodies, and others, administered via oral, parenteral, or other routes. These therapies are distributed through channels including hospital pharmacies, online pharmacies, and retail pharmacies, reaching end users such as hospitals, homecare services, specialty clinics, and others.

The urticaria market consists of sales of corticosteroids, biologics, immunosuppressants, leukotriene receptor antagonists, and topical anti-inflammatory creams or gels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.